/

PXMD

PaxMedica, Inc.Closed

0.0007000.00 0.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.000100

Prev close

0.000700

Day range

0.0001000.000100

52-week range

0.0001000.0200

Volume

3000.22×

Mkt cap

88.39K

P/E ttm

0.00

Fwd P/E

-0.00

EPS ttm

232.68

Div yield

0.00%

Earnings

—

From 52w high

−96.50%

Price Chart

Yahoo Finance · delayed

PXMDOct 12, 2026O 0.0007H 0.0007L 0.0007C 0.00070.0000 (0.00%)

SMA 500.0006
SMA 2000.0005

1Y change +600.00% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PXMD PaxMedica, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +40.00%
1 month: +40.00%
3 months: 0.00%
6 months: −36.36%
Year to date: +600.00%
1 year: +600.00%

Valuation & ownership

Market cap: 88.39K
Enterprise value: −356.46K
P/E (ttm): 0.00
Forward P/E: -0.00
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): 232.68
EPS (forward): -1.09
Beta (5y monthly): -31.82
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 126.26M
Float: —
Short % of float: 4.07%
Short ratio (days): 0.05
Held by insiders: 0.00%
Held by institutions: 0.15%
Avg volume (3m): 1.39K
50-day average: 0.000580
200-day average: 0.000500
52-week change: +600.00%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 57.4
vs 50-day SMA: +19.86%
vs 200-day SMA: +43.74%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 8.97%
Realised vol (20d, ann.): 272.6%
From 52-week high: −96.50%
From 52-week low: +600.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About PaxMedica, Inc.

Yahoo Finance profile

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 6
Headquarters: Tarrytown, NY, United States
Website: paxmedica.com
Officers: Mr. Howard J. Weisman Chief Executive Officer

SEAS

Seasonality · PXMD

2022–2026 · monthly returns

Strongest month Oct +1212.43%Weakest month Nov −41.47%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	300.0	50.0	16.7	-28.6	40.0	-28.6	40.0	0.0	-28.6	40.0			+600.0%
2025	-49.8	-99.7	100.0	-50.0	0.0	0.0	0.0	100.0	-50.0	4900.0	-98.0	0.0	−99.8%
2024	-31.8	22.1	-19.0	46.1	-55.7	-34.1	10.3	-10.4	-48.8	-2.5	-11.4	-35.1	−91.8%
2023	33.0	-23.0	-8.2	-20.4	-11.8	-41.3	-19.6	-28.8	-36.4	-35.2	-70.8	-17.7	−97.8%
2022									-18.9	-12.5	14.3	-15.4	−31.4%

PXMD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PXMD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About PaxMedica, Inc.

Seasonality · PXMD

Insider Activity · PXMD

Congress Trades · PXMD

Investors Holding PXMD

Investors Holding PXMD

Congress Trades · PXMD

Insider Activity · PXMD

Seasonality · PXMD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About PaxMedica, Inc.

Earnings & Dividends

News